Uppsala, Sweden – 26 August 2025
Beactica Therapeutics AB, the Swedish precision medicine company, today announced that BioArctic AB (publ) (Nasdaq Stockholm: BIOA B), as part of their ambition to broaden its pipeline, will evaluate Beactica’s Eclipsor™ technology platform and its potential use within CNS disorders.
Beactica’s Eclipsor™ platform enables the efficient development of allosteric modulators and targeted protein degraders, both of which offer therapeutic potential across multiple disease areas.
"We are proud that BioArctic has chosen to evaluate our Eclipsor technology and hope that this is the start of a long-term relationship to together combat various diseases with a high unmet medical need," said Beactica's CEO, Dr Per Källblad.
About Beactica Therapeutics
Beactica Therapeutics AB is a privately held precision medicine company with a pipeline of novel small molecule therapeutics aimed at treating diseases with significant unmet medical need. Beactica’s approach is centered around the Eclipsor™ platform that enables the efficient development of allosteric modulators and targeted protein degraders. Beactica deliver value to patients and shareholders by advancing its programmes to clinical proof of concept. For more information, please visit www.beactica.com.
Related files:
Read more news from Beactica Therapeutics here.
Stay Updated
Sign up for the Beactica newsletter to receive our latest news and updates